scholarly journals A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome

2019 ◽  
Vol 41 (2) ◽  
pp. 211-216
Author(s):  
Yuko TASHIMA ◽  
Kasumi KUSANAGI ◽  
Yusuke TAKEDA ◽  
Katsuma YOSHIMATSU ◽  
Teruaki ISHIDA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Inflammatory Breast Cancer ◽  
Luminal A ◽  
Trousseau Syndrome

scholarly journals Inflammatory Breast Cancer: Clinical Characteristics and Influence of Molecular Subtypes on Treatment Response

2021 ◽  
Vol 107 (1_suppl) ◽  
pp. 12-12
Author(s):  
D Aissaoui ◽  
M Bohli ◽  
R Ben Amor ◽  
J Yahyaoui ◽  
A Hamdoun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Response ◽  
Inflammatory Breast Cancer ◽  
Hormone Receptor ◽  
Triple Negative ◽  
Molecular Subtypes ◽  
Luminal A ◽  
Her2 Positive ◽  
Luminal B ◽  
Significant Difference

Introduction: Inflammatory Breast Cancer (IBC) is a rare and very aggressive breast cancer with poor prognosis. The prevalence is different from a country to another. In Tunisia, it is about 5 to 7% of breast cancer. The aim of this study is to describe the epidemiological and histopathological features of patients with inflammatory breast cancer and to evaluate the treatment response according to the molecular subtypes. Methods: This retrospective review identified 31 patients with no metastatic IBC treated in our radiotherapy department between December 2019 and November 2020. IBC was confirmed using the clinical criteria. Baseline clinic-pathological and treatment information was retrieved from medical records. Statistical analysis was performed with IBM SPSS V.20. Results: Median age was 51.3 years [27-68]. 48% of tumors were grade 3. The average tumor size was 36mm [10-90]. The histological type was ductal carcinoma in 97%. Vascular invasion was noted in 24 patients (77%). Thirty patients were classified as stage IIIB and one patient was IIIC. 74% were hormone receptor positive and 45% were HER2 positive. Luminal B was the predominant subtype (52%) followed by Her2 positive (32%), Luminal A (23%), and triple negative (3%) All patients had chemotherapy: neoadjuvant for 26 patients (84%) and adjuvant for 5 patients (16%). Nine patients (29%) had tumor pathological complete response (pCR). Partial response was observed in 18 patients (58%). Lymph node pCR was noted in 16% of cases (n=5). Endocrine therapy and trastuzumab were given to 76% and 45% of patients, respectively. The influence of the molecular subtype was not statistically significant on the response to neoadjuvant treatment. The highest rate of pCR were 43% for Her2positive, then 27%, 21% and 9% for Luminal B, Luminal A and Triple negative, respectively (p=0.2). Conclusion: Our study showed a high percentage of hormone receptor and Her2+ (74% and 45% respectively) in IBC. Luminal B was the most frequent subtype. Anthracycline-based chemotherapy and trastuzumab improved the pCR rate: 44% for Her2positive. Triple negative showed poorer pCR than other breast cancer subtype without a significant difference. A larger study is warranted to confirm our findings.

scholarly journals Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature

2021 ◽  
pp. 1071-1079
Author(s):  
Jennifer Y. Ge ◽  
Beth Overmoyer
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Inflammatory Breast Cancer ◽  
Targeted Therapies ◽  
De Novo ◽  
Review Of The Literature ◽  
Her2 Positive ◽  
Rare Type ◽  
Favorable Prognosis ◽  
Poor Outcomes

Inflammatory breast cancer (IBC) is a rare type of breast cancer that is associated with poor outcomes compared with non-IBC. Overexpression of HER2 is enriched in IBC, and those with HER2-positive disease have a relatively favorable prognosis, with improved survival over the last two decades driven by the advent of novel targeted therapies. Here, we present two patients who have survived for over 10 years after being diagnosed with de novo metastatic HER2-positive IBC. We review the data for the treatments available for metastatic HER2-positive IBC and the evolving treatment recommendations for this disease.

Case report of bilateral inflammatory breast cancer

2009 ◽  
Vol 19 (4) ◽  
pp. 558-560 ◽  
Author(s):  
Y.A. MASANNAT ◽  
M. PETER ◽  
P. TURTON ◽  
A.M. SHAABAN
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Inflammatory Breast Cancer

Metastatic Ovarian Serous Carcinoma Presenting as Inflammatory Breast Cancer: A Case Report

2010 ◽  
Vol 29 (3) ◽  
pp. 243-247 ◽  
Author(s):  
Dana Gingell ◽  
Amber Samuel ◽  
Denise Haynik ◽  
William McBee ◽  
Joseph Kelley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Inflammatory Breast Cancer ◽  
Serous Carcinoma ◽  
Ovarian Serous Carcinoma

scholarly journals A CASE OF INFLAMMATORY BREAST CANCER AFTER AUGMENTATION MAMMAPLASTY : CASE REPORT AND REVIEW OF THE JAPENESE LITERATURE

1995 ◽  
Vol 45 (1) ◽  
pp. 121-128 ◽  
Author(s):  
MUREO KASAHARA ◽  
TSUNEHIRO ISHIDA ◽  
TERUO KUSABA ◽  
TOIIRU KOYAMA ◽  
TAKASHI YOSHIDA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Inflammatory Breast Cancer ◽  
Augmentation Mammaplasty

scholarly journals Ovarian Cancer Metastatic to the Breast Presenting as Inflammatory Breast Cancer: A Case Report and Literature Review

2010 ◽  
pp. 27-31 ◽  
Author(s):  
Rebecca L. Klein ◽  
Amanda R. Brown ◽  
Christian M. Gomez-Castro ◽  
Setsuko K. Chambers ◽  
Janiel M. Cragun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Case Report ◽  
Literature Review ◽  
Inflammatory Breast Cancer

scholarly journals Inflammatory Breast Cancer: A Case Report

Breast Care ◽  
2009 ◽  
Vol 4 (6) ◽  
pp. 397-399 ◽  
Author(s):  
Zacharoula Sidiropoulou ◽  
Lurdes Ramalho ◽  
Rosa Madureira
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Inflammatory Breast Cancer

Bolus electron conformal therapy for the treatment of recurrent inflammatory breast cancer: a case report

2012 ◽  
Vol 37 (2) ◽  
pp. 208-213 ◽  
Author(s):  
Michelle M. Kim ◽  
Rajat J. Kudchadker ◽  
James E. Kanke ◽  
Sean Zhang ◽  
George H. Perkins
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Inflammatory Breast Cancer ◽  
Conformal Therapy
Sign in / Sign up

Export Citation Format

Share Document